Anagenics Limited (ASX:AN1) Voluntary Suspension Announcement

Anagenics Limited (ASX:AN1) has requested a voluntary suspension from quotation under Listing Rule 17.2, pending the release of an announcement regarding its proposed restructure and financing to fund the ongoing operations critical to its financial viability. The company aims to manage its continuous disclosure obligations during this period.

Executive Commentary on Voluntary Suspension

The voluntary suspension is necessary to facilitate the management of our continuous disclosure obligations while we work towards finalizing the restructuring of the business and securing the necessary financing for our ongoing operations. We are actively engaged in discussions with third parties to ensure the successful completion of the restructuring, which is crucial for our continued financial sustainability. We are committed to providing further updates as soon as practicable.

Summary of AN1 Voluntary Suspension and Future Outlook

Anagenics Limited (ASX:AN1) has voluntarily suspended its securities from quotation to manage its continuous disclosure obligations pending an announcement regarding the proposed restructure and financing for ongoing operations. The company's aim is to secure the necessary funding and finalize the restructuring, which is critical for its financial viability. The company is working towards providing further updates by the commencement of normal trading on Monday, 9 September 2024, and is committed to ensuring the successful completion of the restructuring to support its continued financial sustainability.